最新ニュース DoorDash (NASDAQ:DASH) 株価情報

DOORDASH INC - A

DoorDash

Founded in 2013 and headquartered in San Francisco, DoorDash is an online delivery demand aggregator. Consumers can use its app to order food items on-demand for delivery or in-store from merchants. Through the acquisition of Wolt in 2022, the firm also provides this service in Europe and Asia. DoorDash creates a marketplace for merchants to establish a presence online, market their offerings, and meet demand through delivery. The firm provides similar service to nonrestaurant businesses, such as grocery, retail, and pet supplies. Dash is also rolling out nascent technology like drone delivery in an effort to continually innovate and provide the best possible service to supply-side and demand-side contingents of its marketplace.

DoorDash Inc

Dash - United States Dollar

Kinross Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.23 by 30.43 percent. This is a 200 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $1.50 billion which beat the analyst consensus estimate of $1.43 million by 105.02K percent. This is a 38.51 percent increase over sales of $1.08 billion the same period last year.

Earnings

Earnings Beats

News

Kinross Gold Q1 Adj. EPS $0.30 Beats $0.23 Estimate, Sales $1.50B Beat $1.43M Estimate

WIIM

VSTE

Vast Renewables shares are trading lower after the company announced it voluntarily delisted from the Nasdaq.

InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect InflaRx to report an earnings per share (EPS) of $-0.17.
The market awaits InflaRx's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.19 in the last quarter, leading to a 1.59% increase in the share price on the following day.
Here's a look at InflaRx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.28</td>
<td>-0.27</td>
<td>-0.21</td>
<td>-0.24</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.09</td>
<td>-0.33</td>
<td>-0.26</td>
<td>-0.18</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>3.0%</td>
<td>3.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746565298_0.png" alt="eps graph" />
<h3>Performance of InflaRx Shares</h3>
Shares of InflaRx were trading at $1.65 as of May 05. Over the last 52-week period, shares are up 34.17%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/IFRX/earnings">To track all earnings releases for InflaRx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IFRX

Preview: InflaRx's Earnings

In the last three months, 9 analysts have published ratings on NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated NeoGenomics and provided 12-month price targets. The average target is $12.94, accompanied by a high estimate of $18.00 and a low estimate of $8.50. This current average represents a 31.1% decrease from the previous average price target of $18.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1746565266_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of NeoGenomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$9.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.50</td>
<td>$18.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NeoGenomics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NeoGenomics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NeoGenomics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NEO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NeoGenomics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into NeoGenomics's Background</h2>
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
<h3>Unraveling the Financial Story of NeoGenomics</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: NeoGenomics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 7.55%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NeoGenomics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -15.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.9%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.6%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of 0.68, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing NeoGenomics: Insights From 9 Financial Analysts

One year ago, we established a concentrated position in shares of&nbsp;CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>). Since our purchases in May 2024,&nbsp;CVS shares have generated a total return of 25% reflecting initial progress in the long-term cultural and operational turnaround underway at the Company. &nbsp;Our position size afforded us the scale necessary to constructively engage with the Board, Management, and fellow Shareholders in Q3 2024 on a multi-faceted performance improvement plan:
<ol>
<li>Board Refreshment&nbsp;– The Board welcomed four new Directors including Larry Robbins, Glenview's CEO, and recently appointed a strong Lead Independent Director.&nbsp; The entire Board is operating cooperatively and cohesively; &nbsp;</li>
<li>Strengthening Culture and Leadership&nbsp;– CVS's leadership has undergone significant transformation under new CEO David Joyner's leadership, combining internal promotion with external recruitment while strengthening a customer-centric, accountable culture; &nbsp;</li>
<li>Operational Intensity&nbsp;– CVS exceeded consensus earnings expectations over the past two quarters and has seen operating strength and early signs of recovery across its businesses; &nbsp;</li>
<li>Risk Management&nbsp;– The Company has suspended material acquisitions, committed to deleveraging, strengthened its insurance reserve levels and established a clear path to sustainable returns on capital that will fuel future customer service and benefit stability; &nbsp;</li>
<li>Portfolio Enhancement and Innovation&nbsp;– CVS has exited or transitioned certain lines of business where economics prevent a sustainable commitment to customers while leading the industry with transparent and value-added solutions to reduce cost and complexity; and &nbsp;</li>
<li>Opportunistic Capital Deployment&nbsp;– In combination, CVS has marched closer to the time in which share repurchase can be both a responsible consideration and a creator of long-term shareholder value.&nbsp;</li>
</ol>
Following healthy Q1 results and increased annual guidance, Glenview reduced its overall holdings by 3.75 million shares consistent with our fund's diversification parameters and to create buying power for further unique opportunities in this volatile macro environment.&nbsp;With this rebalancing, CVS Health remains our largest position, and we have no plans for additional adjustments to our CVS holdings.&nbsp; Our confidence in the near, medium, and long-term outlook for CVS remains strong.&nbsp;
We are grateful for the engagement and enthusiasm of the entire CVS Health team in the revitalization efforts well underway and are fully committed to making continued contributions to the vitality and long-term success of this iconic institution that strengthens the health of 185 million people.
Together we grow.
&nbsp;

Management

Glenview Capital Issues Statement On CVS Health; Highlights 25% Return On CVS Health Investment Since May 2024 As Turnaround Gains Traction, Citing Board Refresh, Cultural And Leadership Overhaul Under New CEO, Operational Gains, Deleveraging, Strategic Business Exits, And Renewed Capital Discipline; Says CVS Remains Firm's Largest Holding After Modest Rebalancing

Electronic Arts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) released its fourth-quarter results after Tuesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/05/b45235130/electronic-arts-reports-q4-and-fy25-results">from the quarter.</a>
The Details: Electronic Arts reported quarterly earnings of $1.58 per share, which beat the analyst consensus estimate of $1.09. Quarterly revenue clocked in at $1.8 billion, beating the consensus estimate of $1.56 billion.
Read Next:&nbsp; <a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take?utm_source=articleShare">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a>
For the fourth quarter and fiscal year, Electronic Arts reported: 
<ul>
<li>Net bookings of $7.355 billion.</li>
<li>The EA SPORTS portfolio delivered another record net bookings year. </li>
<li>EA&#8217;s American Football franchise reached over $1 billion in net bookings. </li>
<li>The Sims franchise saw double-digit growth in the quarter.</li>
<li>In EA SPORTS FC, player monetization was up double digits, starting with the mid-January gameplay update.</li>
<li>Split Fiction has sold nearly 4 million units since its launch in March.</li>
</ul>
&#8220;The incredible success of College Football and the enduring strength of FC drove another record year for EA SPORTS, while The Sims capped FY25 with a historic Q4,&#8221; said Andrew Wilson, CEO of Electronic Arts. 
&#8220;As we look to the future, we&#8217;re confident in our ability to execute across a deep pipeline — beginning this summer with the highly anticipated reveal of Battlefield, a pivotal step in delivering on our next generation of blockbuster entertainment,&#8221; Wilson added. 
Outlook:&nbsp;The company expects fiscal year 2026 net bookings to be approximately $7.6 billion to $8 billion and net revenue to be approximately $7.1 billion to $7.5 billion. 
EA Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Electronic Arts stock was up 5.47% after-hours at $163 on Tuesday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45228179/upwork-delivers-solid-start-to-2025-analyst?utm_source=articleShare">Upwork Delivers &#8216;Solid Start To 2025&#8217;: Analyst&nbsp;</a></li>
</ul>
Image: Shutterstock

Gaming

After-Hours Center

Movers

General

Electronic Arts Stock Climbs After Better-Than-Expected Q4 Report

In the preceding three months, 13 analysts have released ratings for Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Foot Locker and provided 12-month price targets. The average target is $18.85, accompanied by a high estimate of $24.00 and a low estimate of $12.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.09%. 
<img src="https://www.benzinga.com/files/images/story/2025/1746565251_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Foot Locker among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Foot Locker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Foot Locker compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Foot Locker's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Foot Locker's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Foot Locker analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Foot Locker</h2>
Foot Locker Inc operates footwear and apparel retailer in North America, Europe, Australia, New Zealand, and Asia, and has licensed store presence in the Middle East, Europe, and Asia. The company mainly sells athletically inspired shoes and apparel. Foot Locker's merchandise comes from only a few suppliers, with Nike providing the majority. Its portfolio of brands includes Foot Locker, Kids Foot Locker, Champs Sports, WSS, and atmos. The company has omnichannel capabilities to bridge the digital world and physical stores, including order-in-store, buy online and pickup-in-store, and buy online and ship-from-store, as well as e-commerce. It has three operating segments, North America, EMEA, and Asia Pacific.
<h3>Foot Locker's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Foot Locker's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately -5.7% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Foot Locker's net margin is impressive, surpassing industry averages. With a net margin of 2.18%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Foot Locker's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.7%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Foot Locker's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.72%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.96.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

13 Analysts Assess Foot Locker: What You Need To Know

Ratings for Corebridge Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.11, a high estimate of $43.00, and a low estimate of $28.00. Highlighting a 4.14% decrease, the current average has fallen from the previous average price target of $37.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1746565241_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Corebridge Financial by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$28.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Corebridge Financial. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Corebridge Financial compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Corebridge Financial's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Corebridge Financial's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CRBG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Corebridge Financial analyst ratings.</a>
<h2>All You Need to Know About Corebridge Financial</h2>
Corebridge Financial Inc provides retirement solutions and insurance products in the United States. It offers a broad set of products and services through five segments Individual Retirement, Group Retirement, Life Insurance, Institutional Markets businesses, Corporate and Other. The majority of its revenue derives from the Individual Retirement segment.
<h3>Breaking Down Corebridge Financial's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Corebridge Financial's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 142.69%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Corebridge Financial's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 30.62%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Corebridge Financial's ROE stands out, surpassing industry averages. With an impressive ROE of 17.32%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Corebridge Financial's ROA excels beyond industry benchmarks, reaching 0.55%. This signifies efficient management of assets and strong financial health.
Debt Management: Corebridge Financial's debt-to-equity ratio is below the industry average. With a ratio of 1.08, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRBG

Demystifying Corebridge Financial: Insights From 9 Analyst Reviews

AVDX

AvidXchange Holdings shares are trading higher after the company announced it entered into a definitive agreement to be acquired by TPG in partnership with Corpay for a valuation of $2.2 billion.

Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) has outperformed the market over the past 20 years by 11.71% on an annualized basis producing an average annual return of 19.9%. Currently, Quanta Services has a market capitalization of $47.10 billion. 
Buying $1000 In PWR: If an investor had bought $1000 of PWR stock 20 years ago, it would be worth $37,108.64 today based on a price of $317.65 for PWR at the time of writing.
<h3>Quanta Services's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746565237_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Quanta Services Stock In The Last 20 Years

Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $0.01 by 3100 percent. The company reported quarterly sales of $245.90 million which beat the analyst consensus estimate of $240.91 million by 2.07 percent. This is a 19.48 percent decrease over sales of $305.39 million the same period last year.

Earnings Misses

ANGI

Angi Q1 EPS $(0.30) Misses $0.01 Estimate, Sales $245.90M Beat $240.91M Estimate

Analysts' ratings for Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Reinsurance Gr and provided 12-month price targets. The average target is $246.73, accompanied by a high estimate of $270.00 and a low estimate of $216.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.93%. 
<img src="https://www.benzinga.com/files/images/story/2025/1746565234_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Reinsurance Gr among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$248.00</td>
<td>$246.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$246.00</td>
<td>$264.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$216.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$237.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$264.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$263.00</td>
<td>$244.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$233.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$242.00</td>
<td>$252.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Reinsurance Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Reinsurance Gr compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Reinsurance Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Reinsurance Gr's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RGA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Reinsurance Gr analyst ratings.</a>
<h2>About Reinsurance Gr</h2>
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
<h3>Reinsurance Gr's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Negative Revenue Trend: Examining Reinsurance Gr's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -16.67% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Reinsurance Gr's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.42% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Reinsurance Gr's ROA stands out, surpassing industry averages. With an impressive ROA of 0.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Reinsurance Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.5.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

11 Analysts Have This To Say About Reinsurance Gr

In the current market session, Wynn Resorts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) share price is at $81.51, after a 1.77% drop. Over the past month, the stock spiked by 26.35%, but over the past year, it actually decreased by 12.77%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1746565224_0.png" alt="Past Year Chart" />

<h3>Comparing Wynn Resorts P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 31.96 in the Hotels, Restaurants &amp; Leisure industry, Wynn Resorts Inc. has a lower P/E ratio of 19.08. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1746565224_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

WYNN

Price Over Earnings Overview: Wynn Resorts

9 analysts have shared their evaluations of Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Allison Transmission and provided 12-month price targets. The average target is $103.33, accompanied by a high estimate of $115.00 and a low estimate of $94.00. Experiencing a 9.36% decline, the current average is now lower than the previous average price target of $114.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1746565222_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Allison Transmission by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$94.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Luke Junk</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Tim Thein</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$98.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$108.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Allison Transmission. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Allison Transmission compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Allison Transmission's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Allison Transmission's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALSN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Allison Transmission analyst ratings.</a>
<h2>Get to Know Allison Transmission Better</h2>
Allison Transmission is the largest manufacturer of fully automatic transmissions for commercial vehicles. The company's automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business has about 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motor homes). Allison also produces electric hybrid propulsion systems and is developing e-powertrains.
<h3>Allison Transmission's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: Allison Transmission's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -2.92%. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Allison Transmission's net margin is impressive, surpassing industry averages. With a net margin of 25.07%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 11.58%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.59%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.44, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALSN

Expert Outlook: Allison Transmission Through The Eyes Of 9 Analysts

Across the recent three months, 4 analysts have shared their insights on James River Gr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for James River Gr Hldgs, revealing an average target of $6.06, a high estimate of $8.00, and a low estimate of $5.00. Experiencing a 12.68% decline, the current average is now lower than the previous average price target of $6.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1746565212_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive James River Gr Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Casey Alexander</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.25</td>
<td>$7.75</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to James River Gr Hldgs. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of James River Gr Hldgs compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for James River Gr Hldgs's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of James River Gr Hldgs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JRVR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on James River Gr Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know James River Gr Hldgs Better</h2>
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.
<h3>James River Gr Hldgs's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: James River Gr Hldgs's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -41.9%. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: James River Gr Hldgs's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -74.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): James River Gr Hldgs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -18.97%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): James River Gr Hldgs's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.89%, the company may face hurdles in achieving optimal financial returns.
Debt Management: James River Gr Hldgs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JRVR

4 Analysts Assess James River Gr Hldgs: What You Need To Know

VSTS

Vestis shares are trading lower after the company reported worse-than-expected Q2 financial results.

Warren Buffett officially named Greg Abel as his successor to become CEO of Berkshire Hathaway, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) at the annual shareholder meeting last Saturday. Buffett said he will remain chairman of the board, ensuring continuity and mentorship during <a href="https://www.benzinga.com/25/05/45215578/warren-buffett-cared-so-much-about-shareholders-he-told-them-about-his-retirement-plans-before-even-telling-the-board-or-greg-abel-says-monsoon-pabrai">the leadership transition.&nbsp;</a>
Abel is notably private and has rarely granted interviews to the business media. Even as he ascended to one of the most prominent corporate roles in America, he has maintained a low public profile.&nbsp;
Here are some of the lesser-known facts that reveal the man behind the CEO title, and how he quietly became one of the most influential figures in American business.
Read Next: <a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take?utm_source=articleShare">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a>
Humble Beginnings: Abel was born to a working-class family in Edmonton, Alberta, Canada, and has described his upbringing as family-oriented and rooted in a traditional, supportive environment. 
He took on odd jobs like filling fire extinguishers, delivering advertising flyers to homes and collecting used bottles for change. Abel's modest upbringing helped to shape his work ethic and grounded personality.&nbsp;
Major Hockey Fan: Outside the boardroom, Abel is a huge hockey enthusiast. He currently serves as an assistant volunteer coach for his son's hockey team in Des Moines, Iowa, reflecting his continued connection to his Canadian roots and his commitment to family
Stanley Cup Connection: Not only is Abel an avid ice hockey fan, but he also has a Stanley Cup connection. His uncle, Sid Abel, was a Hall of Fame hockey player who won the Stanley Cup three times with the Detroit Red Wings in 1943, 1950 and 1952. Sid Abel also coached and served as the team's general manager.&nbsp;
Warren Buffett's Neighbor?: In the 1990s, Abel lived just a few blocks away from Buffett in Omaha, Nebraska, for six years. Interestingly, the two never met during that time despite their proximity. 
Not Moving to Omaha: Even as incoming CEO, Abel plans to continue living in Des Moines, Iowa, where Berkshire Hathaway Energy is based, rather than relocating to Berkshire's Omaha headquarters.&nbsp;
Abel played a key role in transforming Berkshire Hathaway Energy into a major industry player through a series of acquisitions and making it one of Berkshire's "four jewels." He is set to take over as CEO of Berkshire Hathaway on Jan. 1, 2026.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

5 Facts You Might Not Know About Warren Buffett's Successor Greg Abel

MYGN

Myriad Genetics shares are trading lower after the company reported a Q1 sales miss and cut its FY25 guidance below estimates.

CPAY

AvidXchange Enters Into A Definitive Agreement To Be Acquired By TPG In Partnership With Corpay; TPG And Corpay Will Acquire AvidXchange For $10.00 Per Share In A Cash Transaction That Values The Company At $2.2B

NRDS

NerdWallet shares are trading higher after the company reported better-than-expected Q1 sales results and issued Q2 sales guidance above estimates.

Press Releases

Domino's® and DoorDash Announce Partnership: World's Largest Pizza Company to Join Largest Local Commerce Platform in North America

DoorDash and Coco Expand Global Partnership with U.S. Sidewalk Robot Delivery Launch

Giant Tiger Partners with DoorDash and Uber Eats, Increasing Convenient On-Demand Delivery Access for Canadians

DoorDash CFO to Participate in Fireside Chat at Upcoming Investor Conference

Brenda Song Stars in DoorDash Mother's Day Campaign To Give Mom a Break

"IT'S ON THE ROCK!" TEREMANA® TEQUILA'S ANNUAL "GUAC ON THE ROCK" CAMPAIGN RETURNS, NOW GIVING AWAY UP TO $1M FOR ANY APPETIZER, AND AVAILABLE THROUGH DOORDASH

DoorDash Announces Date and Time Change of First Quarter 2025 Financial Results and Conference Call

DoorDash Announces Agreement to Acquire Deliveroo

DoorDash Releases First Quarter 2025 Financial Results

DoorDash Announces Agreement to Acquire SevenRooms to Enhance Commerce Platform Offerings

DASH

Arcos Dorados Holdings Inc. Class A Shares

Arcos Dorados Holdings

Aramark

Biglari Holdings Inc. Class A Common Stock

BJ's Restaurants

Dutch Bros

The Cheesecake Factory Incorporated - Common Stock

Cheesecake Factory

Cava Group

Cracker Barrel Old Country Store, Inc. - Common Stock

Cracker Barrel Old

Chipotle Mexican Grill, Inc. Common Stock

Chipotle Mexican Grill

Domino's Pizza

Darden Restaurants

Brinker International

First Watch Restaurant Group, Inc. - Common Stock

First Watch Restaurant Gr

SUPER HI INTERNATIONAL HOLDING LTD. - American Depositary Shares

Super Hi International

Kura Sushi USA, Inc. - Class A Common Stock

Kura Sushi USA

McDonald's

Papa John's International, Inc. - Common Stock

Papa John's International

Starbucks

Sweetgreen

Shake Shack

Texas Roadhouse

Wendy's

Wingstop

Yum Brands

Yum China Holdings

JMP Securities

Morgan Stanley

Cantor Fitzgerald

Keybanc

JP Morgan

Screenshot 2024-11-07 at 6.41.21 PM

Emerging Markets

Movers & Shakers

UBER

Innovation Beverage Group Offers Zero-Alcohol Range As Non-Alcoholic Beverages Market Grows

DoorDash shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, the company announced it will acquire SevenRooms.

Comments

DoorDash

ニュース

最新ニュース DoorDash (NASDAQ:DASH) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル